Zobrazeno 1 - 10
of 93
pro vyhledávání: '"H H, Sedlacek"'
Publikováno v:
Experimental and Toxicologic Pathology. 44:317-324
Summary Two monoclonal antibodies (mabs) were raised against ganglioside GD2 (Gtri2) and tested on human intracranial tumors and normal brain by immunohistochemical methods both in frozen and paraffin embedded sections. In normal brain structures, as
Autor:
H. H. Sedlacek
Publikováno v:
Drugs. 59(3)
The most essential kinases involved in cell membrane receptor activation, signal transduction and cell cycle control or programmed cell death and their interconnections are reviewed. In tumours, the genes of many of those kinases are mutated or ampli
Autor:
D W, Miller, W, Graulich, B, Karges, S, Stahl, M, Ernst, A, Ramaswamy, H H, Sedlacek, R, Müller, J, Adamkiewicz
Publikováno v:
International journal of cancer. 81(4)
Endoglin/CD105 is a membrane protein involved in the TGF-beta receptor signalling pathway. Endoglin expression has been reported to be selective for a few cell types, in particular endothelial cells, although a number of conflicting reports have been
Publikováno v:
International journal of cancer. 77(1)
The anti-tumor drug Flavopiridol is a potent inhibitor of cyclin-dependent kinases (cdks). As a consequence, Flavopiridol-treated cells arrest in both G1 and G2, but Flavopiridol has also been shown to be cytotoxic for some tumor cell lines. The unde
Autor:
H H, Sedlacek
Publikováno v:
Critical reviews in oncogenesis. 5(6)
Tumors are resistant to the immune response as evidenced by both their progressive growth in patients despite specific humoral and cellular immune responses to tumor antigens and by the moderate clinical effect of active specific immunotherapy with t
Autor:
G. Seemann, A. Schwarz, A. Steinstraesser, H. H. Sedlacek, P. Hermentin, K. Bosslet, M. Magerstaedt, A. Bruynck, L. Kuhlmann
Publikováno v:
Clinical Use of Antibodies ISBN: 9789401055550
Starting from the moderate therapeutic effects of MAb guided radioimmunotherapyin the treatment of carcinomas, we presented a two phase radioimmunotherapy concept based on bispecific MAbs which might be more effective. To work out this concept we fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bca2e656723ef8b15db79321096ab214
https://doi.org/10.1007/978-94-011-3516-0_6
https://doi.org/10.1007/978-94-011-3516-0_6
Publikováno v:
Behring Institute Mitteilungen. (87)
The distribution of the monoclonal antibody (MAb) BW494 in human pancreatic carcinoma biopsies during high dose i.v. immunotherapy was investigated. Using immunohistochemical techniques combined with anti-idiotypic, endothelial cell specific and bisp
Publikováno v:
Behring Institute Mitteilungen. (87)
The application of monoclonal antibodies (MAb) of non human origin in the treatment of human diseases is hampered by the immunogenicity of those molecules in patients. The development of molecular biology provides us with the opportunity to overcome
Publikováno v:
The British journal of cancer. Supplement. 10
The distribution of the monoclonal antibody (MAb) BW494 in human pancreatic carcinoma biopsies during high dose intravenous immunotherapy was investigated. Using immunohistochemical techniques combined with anti-idiotypic, endothelial cell-specific a
Publikováno v:
International Journal of Cancer. 15:409-416
The effect on tumor progression produced by the injection of VCN-treated tumor cells in dogs with spontaneous mammary tumors was investigated. Untreated dogs of different races and different ages with at least two palpable spontaneous mammary tumors